Form 4: Sutro Biopharma CSO Reports Routine Equity Transactions

Sentiment:

Insider Transaction Report 3 March 2026 6:56 PM

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, reported the acquisition of common stock through RSU settlements and subsequent tax-related dispositions, alongside new RSU and stock option grants.

Summary

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, Inc. (STRO), reported multiple transactions related to his beneficial ownership.
On March 1, 2026, Gerber acquired 1,125 shares of common stock from the settlement of Restricted Stock Units (RSUs) and disposed of 463 shares at $20.47 to cover income tax withholding obligations.
On March 2, 2026, he acquired 2,843 shares of common stock from RSU settlements and disposed of 1,170 shares at $20.55 for tax withholding purposes.
Additionally, on March 2, 2026, Gerber was granted 5,000 new Restricted Stock Units (RSUs) and 40,000 stock options with an exercise price of $20.55.
All reported amounts, including dollar values, have been adjusted to reflect a 1-for-10 reverse stock split effective December 3, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the new grants of RSUs and stock options to a key executive, which aligns management incentives with shareholder value, despite the routine tax-related dispositions.

Positives

Grant of 5,000 new Restricted Stock Units (RSUs) to the Chief Scientific Officer, aligning management incentives with long-term company performance.
Grant of 40,000 new stock options to the Chief Scientific Officer, providing further incentive for future value creation.

Negatives

Disposition of 463 shares at $20.47 and 1,170 shares at $20.55 to satisfy tax withholding obligations, which are not sales initiated by the reporting person but reduce direct beneficial ownership.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider equity transactions, such as RSU settlements and tax withholdings, are common in the biotechnology sector as a form of executive compensation and do not typically signal a change in company fundamentals or strategic direction. The grants of new RSUs and stock options are standard practice to incentivize long-term performance.

Comparison to Industry Standards

StockSavvy.ai observes that the vesting schedules (annual for RSUs, monthly for options over 4 years) and the use of equity compensation are consistent with common practices for executive compensation in the biotechnology and pharmaceutical industries.
Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar long-term incentive structures to retain and motivate key scientific and executive talent.

Stakeholder Impact

Shareholders: The grants of new equity incentives to the Chief Scientific Officer could positively impact long-term shareholder value by aligning executive interests with company performance.
Employees: The filing reflects standard equity compensation practices, which are a key component of employee retention and motivation strategies within the company.

Next Steps

Continued vesting of 5,000 new Restricted Stock Units (RSUs) annually, with the first tranche vesting on March 1, 2027.
Continued monthly vesting of 40,000 stock options, with the first tranche vesting on April 1, 2026.
Ongoing beneficial ownership of 9,518 common shares, 5,000 RSUs, and 40,000 stock options, subject to future vesting and transactions.

Key Dates

Date	Description
2025-03-01	First tranche vesting date for a portion of previously granted RSUs.
2025-12-02	Certificate of Amendment for 1-for-10 Reverse Stock Split filed with Delaware Secretary of State.
2025-12-03	Effective date of the 1-for-10 reverse stock split.
2026-03-01	Transaction date for RSU settlement and tax withholding; first tranche vesting date for a portion of previously granted RSUs.
2026-03-02	Transaction date for RSU settlement, tax withholding, and new RSU and stock option grants.
2026-03-03	Signature date of the reporting person's attorney-in-fact on the Form 4.
2026-04-01	First tranche vesting date for 1/48 of the 40,000 stock options granted.
2027-03-01	First tranche vesting date for 1/4 of the 5,000 new RSUs granted.
2028-03-01	Expiration date for 1,125 Restricted Stock Units.
2029-03-02	Expiration date for 2,843 Restricted Stock Units.
2030-03-01	Expiration date for 5,000 Restricted Stock Units.
2036-03-02	Expiration date for 40,000 Stock Options.

Recommendation

hold

This Form 4 filing details routine insider transactions related to equity compensation, including RSU settlements, tax withholdings, and new grants of RSUs and stock options. While the new grants are a positive for aligning executive incentives, these are standard compensation events and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Sutro Biopharma, STRO, SEC Form 4, Insider Trading, Hans-Peter Gerber, Chief Scientific Officer, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Reverse Stock Split, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.